tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
David-Neto E et al. Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. 2017 Transplantation pmid:27798513
Jain A et al. Pregnancy after liver transplantation under tacrolimus. 1997 Transplantation pmid:9293865
Farid SG et al. Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. 2009 Transplantation pmid:19502974
Garcia-Criado FJ et al. Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. 1997 Transplantation pmid:9293871
Suzuki H et al. Induction of transplantation tolerance in adult rats by vascularized spleen transplantation. 1997 Transplantation pmid:9293881
First MR Transplantation in the nineties. 1992 Transplantation pmid:1370734
Satterthwaite R et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. 1998 Transplantation pmid:9484771
Stevens RB et al. Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. 2008 Transplantation pmid:18497677
Sheikh AM et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. 1999 Transplantation pmid:10440408
Furukawa H et al. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. 2000 Transplantation pmid:10670633
Moxey-Mims MM Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) 1999 Transplantation pmid:10440413
Jordan ML et al. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. 2000 Transplantation pmid:10670637
Asako H et al. Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. 1992 Transplantation pmid:1384191
Yun J et al. Bilateral ischemic optic neuropathy in a patient using tacrolimus (FK506) after liver transplantation. 2010 Transplantation pmid:20559109
Kim YI et al. Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. 1992 Transplantation pmid:1373539
Kato T et al. Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder. 2011 Transplantation pmid:21747275
Pratschke J et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. 1997 Transplantation pmid:9326428
Ashokkumar C et al. Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. 2011 Transplantation pmid:21747326
McGhee B et al. Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. 1997 Transplantation pmid:9326429
High KP The antimicrobial activities of cyclosporine, FK506, and rapamycin. 1994 Transplantation pmid:7517076
Berenguer M et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. 2010 Transplantation pmid:21068701
Cosio FG et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. 2007 Transplantation pmid:17318073
Yoshimura N et al. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. 1994 Transplantation pmid:7517078
Tuteja S et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. 2001 Transplantation pmid:11397967
Casey MJ et al. Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. 2014 Transplantation pmid:24717218
Maes BD et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. 2001 Transplantation pmid:11726827
Stifft F et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. 2014 Transplantation pmid:24686426
Kahan BD An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. 1999 Transplantation pmid:10428260
Washburn K et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. 2001 Transplantation pmid:11726831
Toso C et al. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients. 2003 Transplantation pmid:14557767
Reichenspurner H et al. Optimization of the immunosuppressive protocol after lung transplantation. 1999 Transplantation pmid:10428269
Pilmore HL et al. Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. 2001 Transplantation pmid:11726837
Sampaio MS et al. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. 2012 Transplantation pmid:22129761
Moxey-Mims MM et al. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) 1998 Transplantation pmid:9521193
Vu MD et al. Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. 2003 Transplantation pmid:12792496
Tzakis AG et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. 2003 Transplantation pmid:12792506
Peloso LJ et al. The serum concentration of tacrolimus after ingesting omeprazole: a pilot study. 2014 Transplantation pmid:25221905
Koenen HJ et al. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. 2003 Transplantation pmid:12792519
Hytiroglou P et al. FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. 1993 Transplantation pmid:7506452
Jain A et al. Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. 2008 Transplantation pmid:18347534
Ishizuka J et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. 1993 Transplantation pmid:7506454
Gallon L et al. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. 2015 Transplantation pmid:25905982
Alhamad T et al. Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy. 2017 Transplantation pmid:28422926
Robertsen I et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. 2015 Transplantation pmid:25148382
Jordan ML et al. Long-term results of pancreas transplantation under tacrolius immunosuppression. 1999 Transplantation pmid:10075592
Khanna AK Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. 2000 Transplantation pmid:10972232
Koh A et al. Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. 2010 Transplantation pmid:20145529
Shapiro R et al. Pediatric renal transplantation under tacrolimus-based immunosuppression. 1999 Transplantation pmid:10075598
Königsrainer A et al. Nonocclusive segmental mesenteric ischemia after combined pancreas kidney transplantation: mycophenolate mofetil as an etiological factor? 2000 Transplantation pmid:10972233
Sofi AA et al. Bullous pemphigoid associated with acute renal allograft rejection. 2010 Transplantation pmid:20145531
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
Takaya S et al. Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. 1992 Transplantation pmid:1279851
Min DI et al. Circadian variation of tacrolimus disposition in liver allograft recipients. 1996 Transplantation pmid:8900327
Gaber AO et al. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. 2008 Transplantation pmid:19005398
Wasik M et al. Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. 1991 Transplantation pmid:1702910
Carroll PB et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. 1991 Transplantation pmid:1702911
Jindal RM et al. Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. 1994 Transplantation pmid:7519799
Mor E et al. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. 1994 Transplantation pmid:7519800
Merkle M et al. The effect of sevelamer on tacrolimus target levels. 2005 Transplantation pmid:16177649
McDevitt-Potter LM et al. A multicenter experience with generic tacrolimus conversion. 2011 Transplantation pmid:21788920
Demmers MW et al. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. 2014 Transplantation pmid:24157471
Eckhoff DE et al. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. 1998 Transplantation pmid:9458011
Roth D et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. 1998 Transplantation pmid:9458023
Opelz G Comparison of FK506 and cyclosporine. 1996 Transplantation pmid:8830844
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. 1989 Transplantation pmid:2465592
Yoshimura N et al. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. 1989 Transplantation pmid:2465593
Jacobson PA et al. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. 2012 Transplantation pmid:22334041
Schneeberger S et al. Cytomegalovirus-related complications in human hand transplantation. 2005 Transplantation pmid:16123716
Berg UB et al. Renal function before and long after liver transplantation in children. 2001 Transplantation pmid:11544422
Thorp M et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. 2000 Transplantation pmid:10762229
Irish W et al. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. 2003 Transplantation pmid:14688516
Murase N et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. 1993 Transplantation pmid:7682735
Gruessner RW et al. Mycophenolate mofetil in pancreas transplantation. 1998 Transplantation pmid:9721799
Emond JC et al. Improved results of living-related liver transplantation with routine application in a pediatric program. 1993 Transplantation pmid:7682738
Chisholm MA et al. Coadministration of tacrolimus with anti-acid drugs. 2003 Transplantation pmid:12973105
Sulanc E et al. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. 2005 Transplantation pmid:16249743
Laskow DA et al. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8878381
Mourad M et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. 2005 Transplantation pmid:16249748
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. 1996 Transplantation pmid:8878382
Iwata H et al. Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. 1993 Transplantation pmid:7687396
Kershner RP and Fitzsimmons WE Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. 1996 Transplantation pmid:8878385
Macedo C et al. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. 2012 Transplantation pmid:22343334
Tanaka A et al. Living related liver transplantation across ABO blood groups. 1994 Transplantation pmid:7522363
Devlin J et al. Nitric oxide generation. A predictive parameter of acute allograft rejection. 1994 Transplantation pmid:7522365
Vincenti F et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. 2002 Transplantation pmid:11907427
Klein A et al. Impact of a pharmaceutical care program on liver transplant patients' compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. 2009 Transplantation pmid:19300186
Beckebaum S et al. Predictive factors of outcome in patients transplanted for hepatitis B. 2009 Transplantation pmid:19300191
Singh N et al. Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. 1994 Transplantation pmid:7524204
Ochiai T et al. Studies of the effects of FK506 on renal allografting in the beagle dog. 1987 Transplantation pmid:2447688
Pascual J et al. Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. 2011 Transplantation pmid:21336083
Konrad T et al. Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus therapy. 2000 Transplantation pmid:10852599
Fredericks S and Holt DW TGF-beta quantitation can be tricky. 1999 Transplantation pmid:10480399
Schvarcz R et al. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). 2000 Transplantation pmid:10852623
Hughes JR et al. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. 1999 Transplantation pmid:10480422
Cacciarelli TV et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1998 Transplantation pmid:9808490
Macphee IA et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. 2005 Transplantation pmid:15729180
Baggio B et al. Relationship between plasma phospholipid polyunsaturated fatty acid composition and bone disease in renal transplantation. 2005 Transplantation pmid:16314806
Ricordi C et al. In vivo effect of FK506 on human pancreatic islets. 1991 Transplantation pmid:1716797
Todo S et al. Small intestinal transplantation in humans with or without the colon. 1994 Transplantation pmid:7512291
Griffith BP et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. 1994 Transplantation pmid:7512292